Advertisement

Advertisement

SCYX Stock Latest News

Scynexis price target raised to $33 from $24 at Guggenheim

The FlyScynexis price target raised to $33 from $24 at Guggenheim

SCYNEXIS: Buy Rating Reaffirmed with $32 Price Target Unchanged Amid Strong Cash Position and Promising Pipeline

PremiumRatings

SCYNEXIS: Buy Rating Reaffirmed with $32 Price Target Unchanged Amid Strong Cash Position and Promising Pipeline

10d ago

Scynexis reports Q2 EPS 63c, consensus (51c)

PremiumThe Fly

Scynexis reports Q2 EPS 63c, consensus (51c)

14d ago

GSK closer to relaunching Brexafemme, says Brookline

PremiumThe Fly

GSK closer to relaunching Brexafemme, says Brookline

24d ago

Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained

PremiumRatings

Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained

2M ago

Scynexis initiates SCY-770 study

PremiumThe FlyScynexis initiates SCY-770 study

2M ago

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

Company Announcements

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

2M ago

Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested

Market News

Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested

3M ago

Scynexis trading halted, news pending

PremiumThe Fly

Scynexis trading halted, news pending

3M ago

SCYNEXIS Stockholders Approve One-for-Eight Reverse Split

PremiumCompany Announcements

SCYNEXIS Stockholders Approve One-for-Eight Reverse Split

3M ago

Scynexis announces 1-for-8 reverse stock split

PremiumThe Fly

Scynexis announces 1-for-8 reverse stock split

3M ago

Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target

PremiumRatings

Buy Rating Reaffirmed on Scynexis as Rare Disease Pivot and Strong Cash Runway Support Unchanged $4 Price Target

3M ago

Scynexis reports Q1 EPS (42c), consensus (12c)

PremiumThe FlyScynexis reports Q1 EPS (42c), consensus (12c)

3M ago

Scynexis files to sell 87M shares of common stock for holders

The Fly

Scynexis files to sell 87M shares of common stock for holders

4M ago

SCYNEXIS Director Steven Gilman Announces Board Retirement

Company Announcements

SCYNEXIS Director Steven Gilman Announces Board Retirement

4M ago

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

PremiumRatings

Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target

4M ago

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

PremiumCompany Announcements

SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease

5M ago

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

PremiumCompany Announcements

SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline

5M ago

SCYNEXIS Raises $40 Million in Strategic Private Placement

PremiumCompany Announcements

SCYNEXIS Raises $40 Million in Strategic Private Placement

5M ago

Poxel announces sale of PXL770 to Scynexis for up to $196M

PremiumThe FlyPoxel announces sale of PXL770 to Scynexis for up to $196M

5M ago

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

The Fly

Scynexis completes acquisition of PXL-770 for treatment of kidney disease

5M ago

Scynexis announces $40M private placement

The Fly

Scynexis announces $40M private placement

5M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >